Latent Tuberculosis clinical trials at UCSF
1 research study open to eligible people
open to eligible people ages 18-65
This study will evaluate the potential drug-drug interactions between dolutegravir (DTG) and steady state rifapentine (RPT) when RPT is given with isoniazid (INH) daily for 4 weeks (1HP) as part of treatment for latent TB infection (LTBI) in HIV-1 and LTBI co-infected individuals.
San Francisco, California and other locations